<DOC>
	<DOC>NCT02345772</DOC>
	<brief_summary>Hormonal therapy with fulvestrant 500 mg to be administered before surgery With docetaxel, Trastuzumab, and pertuzumab to determine pathological complete remission rate at the time of surgery in ER-positive and HER2-positive patients with breast cancer.</brief_summary>
	<brief_title>Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1. Patients ≥ 18 years of age with histologically, and radiographically confirmed nonmetastatic ERpositive (defined as ≥30% of positive cells) and HER2positive (defined as overexpression by immunohistochemistry (3+) or 2+ and positive by defined by fluorescence or dual in situ hybridization.) breast cancer with minimal tumor size over 2 cm (≥T2 lesion) to receive neoadjuvant chemotherapy recommended by the treating physician 2. Eastern Cooperative Oncology Group (ECOG) performance status score &lt; 1 3. Absolute neutrophil count &gt; 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 8.5 g/dL 4. Serum creatinine ≤1.5 times the upper limit of the normal range, total bilirubin ≤ 1.5 X ULN (≤ 3 mg/dL if clinically diagnosed with Gilbert syndrome) AST/ALT ≤ 2.5 X ULN (AST/ALT ≤ 5X ULN if clinically diagnosed with Gilbert syndrome) 5. Women of childbearing potential (i.e., women who are premenoposaul or not surgically sterile) must have a negative serum pregnancy test within 2 weeks prior to beginning treatment 1. Uncontrolled cardiac disease, such as angina, hypertension or significant arrhythmias 2. LVEF (left ventricular ejection fraction) &lt; 50% on any prior assessment. Note: Assessment of LVEF is done before and after trastuzumabbased chemotherapy as standard of care 3. Pregnant or lactating females 4. Inability to complete informed consent process and adhere to the protocol treatment plan and followup requirements 5. Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>